Simple once-daily treatment
Not a steroid. No boxed warning

Pivotal Safety

CONSISTENTLY WELL TOLERATED AND SAFE

SAFE FOR ANY LOCATION1,2

  • Low rates of stinging or burning (1.6%)3*
  • Not associated with folliculitis, atrophy, striae, or HPA-axis suppression1
  • Low rate of discontinuation due to adverse events (1.6%)1

*Low rates of hot, tingling/stinging sensation reported in patient-rated tolerability assessments 10–15 minutes after first application: 1.6% with ZORYVE (n=883) vs 2.0% with vehicle (n=451).

HPA = hypothalamic-pituitary-adrenal.

Insomnia was reported in fewer than 1% of patients treated with ZORYVE.

See Efficacy Data

| |

Learn About the
Formulation

| |

Request a Representative